+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neurological Disorder Drugs Market 2020-2026

  • ID: 5240867
  • Report
  • March 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021
1 of 3

FEATURED COMPANIES

  • AB Science
  • Allergan Plc
  • AstraZeneca Plc
  • Biogen Inc.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • MORE
Global Neurological Disorder Drugs Market Size, Share & Trends Analysis Report by Disorder Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington Disease, and Others), and Forecast 2020-2026.

The global neurological disorder drugs market is projected to grow significantly during the forecast period (2020-2026). The key factors that drive the growth of the market include the rising prevalence of neurological disorders across the globe. The rising geriatric population is another primary factor that drives the growth of the neurological disorder drugs market, as elder people are more prone to such disorders.

Besides, the launch and innovations of novel products by the key players further supports the growth of the market. For instance, in March 2019, a novel drug Mayzent manufactured by Novartis AG was approved by the US FDA for the treatment of adults with relapsing forms of multiple sclerosis, including SPMS with active disease, relapsing-remitting multiple sclerosis (RRMS), and clinically isolated syndrome (CIS). Hence, these factors altogether drive the growth of the market over the forecast period.

The global neurological disorder drugs market is segmented on the basis of disorder type into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington disease, and others. Amongst the disorder type segment, Parkinson’s disease segment is projected to hold a lucrative share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders, some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others.

Geographically, the study of the global neurological disorder drugs market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. The North American region is estimated to grow significantly during the forecast period.

Further, Merck & Co. Inc., Novartis International AG, Boehringer Ingelheim International GmbH, Pfizer inc., Teva Pharmaceutical Industries Ltd., Allergan Plc., AstraZeneca Plc, and Eisai Co., Ltd. are some of the prominent players operating in the global neurological disorder drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.

In September 2019, Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced the manufacturing and marketing approval of Equfina tablets in Japan. The tablet is indicated for the improvement of the wearing-off phenomenon in patients with Parkinson’s disease under treatment with a drug containing levodopa. Equfina tablets contain safinamide mesylate also termed safinamide and Meiji holds the manufacturing and marketing approval for safinamide, and Eisai exclusively sells the safinamide in Japan.

Research Methodology

The market study of the global neurological disorder drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for the pharmaceutical industry, drug manufacturers, hospitals & clinics, research organizations, academic institutes, non-profit organizations, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Neurological Disorder Drugs Market Research and Analysis by Disorder Type
2. The Report covers:
  • Comprehensive research methodology of the global Neurological Disorder Drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Neurological Disorder Drugs market.
  • Insights about market determinants which are stimulating the global Neurological Disorder Drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB Science
  • Allergan Plc
  • AstraZeneca Plc
  • Biogen Inc.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Major Drug Analysis
  • Analgesics
  • Antidepressants
  • Sedatives & Hypnotics
  • Antihypertensive
  • Others
2.3. Analyst Insight & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendations
2.3.3. Conclusion
2.4. Rules & Regulations

3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Merck & Co. Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Teva Pharmaceuticals Industries Ltd.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Pfizer Inc.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Novartis International AG
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Boehringer Ingelheim International GmbH
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global Neurological Disorder Drugs Market by Disorder
5.1.1. Alzheimer’s Disease
5.1.2. Parkinson’s Disease
5.1.3. Multiple Sclerosis
5.1.4. HuntingtonDisease
5.1.5. Others

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. AbbVie Inc.
7.2. AB Science
7.3. ACADIA Pharmaceuticals Inc.
7.4. ApotexInc.
7.5. Axovant Gene Therapies Ltd.
7.6. Allergan Plc
7.7. AstraZeneca Plc
7.8. Bausch Health Companies Inc.
7.9. BayerAG
7.10. Biogen Inc.
7.11. Boehringer Ingelheim International GmbH
7.12. Cipla Ltd.
7.13. Daiichi Sankyo Espha Co., Ltd.
7.14. Eisai Co. Ltd.
7.15. Eli Lilly and Co.
7.16. F. Hoffmann-La Roche Ltd.
7.17. GlaxoSmithKline Plc
7.18. Merck & Co. Inc.
7.19. Novartis International AG
7.20. Otsuka Pharmaceutical Co., Ltd.
7.21. Pfizer Inc.
7.22. Sanofi SA
7.23. Sun Pharmaceutical Industries Ltd.
7.24. Teva Pharmaceutical Industries Ltd.
7.25. Vertical Pharmaceuticals, LLC
7.26. Wockhardt Ltd.
Note: Product cover images may vary from those shown
3 of 3
  • AbbVie Inc.
  • AB Science
  • ACADIA Pharmaceuticals Inc.
  • ApotexInc.
  • Axovant Gene Therapies Ltd.
  • Allergan Plc
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • BayerAG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Daiichi Sankyo Espha Co., Ltd.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertical Pharmaceuticals, LLC
  • Wockhardt Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll